Physician profile
Amir Khan
NPI 1609944586
$659.93
in general payments reported to CMS, 2019-2025
15 companies · $25.19 in 2025
The $25.19 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $47.43 · 2021: $174 · 2022: $20.07 · 2023: $159 · 2024: $57.07 · 2025: $25.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $241.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $229.78 | 2021-2024 | Entyvio |
| Janssen Biotech, INC. | $96.94 | 2019-2023 | Erleada |
| Glaxosmithkline, LLC. | $73.18 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $50.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.53 | 2023 | Xifaxan |
| Laborie Medical Technologies Corp. | $25.19 | 2025 | |
| Genentech USA, INC. | $20.61 | 2019 | |
| Celgene Corporation | $20.07 | 2022 | |
| Janssen Pharmaceuticals, INC | $18.00 | 2019 | |
| Coherus Oncology, INC. | $17.67 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $17.50 | 2020 | |
| Array Biopharma INC | $15.94 | 2023 | Mektovi, Lorbrena, Braftovi |
| Abbvie INC. | $15.94 | 2024 | |
| Pfizer INC. | $15.66 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amir Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.